Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

1.750 +0.040 (+2.34%)
Streaming Delayed Price Updated: 1:48 PM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clearmind Medicine Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
CMND Stock Earnings: Clearmind Medicine Reported Results for Q2 2024 ↗
Clearmind Medicine just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
Why Psychedelic-Pharma Clearmind Medicine Stock Is Moving Higher ↗
Clearmind Medicine shares are trading higher Friday after the company announced advancement in its proprietary MEAI-based binge behavior regulator program through the granting of patent approval in... 
Via Benzinga
Topics Intellectual Property
News headline image
Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Day Trading My Way From Red To Green ↗
I set daily profit goals and max loss limits to manage my risk. My daily goal is $5,000, and I cap my daily loss at the same amount. 
Via Talk Markets
News headline image
Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
What's Going On With Clearmind Medicine Stock Tuesday? ↗
Clearmind said its alcohol substitute was granted patents in the U.S., India and Europe. The company also highlighted that the no/low alcohol category is forecasted to grow at a volume CAGR of more... 
Via Benzinga
Topics Intellectual Property
News headline image
Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Why Clearmind Medicine Stock Is Moving Higher ↗
Clearmind Medicine shares are up Tuesday after the company announced it signed an exclusive patent licensing agreement with Yissum Research Development. 
Via Benzinga
Topics Intellectual Property
News headline image
Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Applies to Cease Being a Reporting Issuer in Canada
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More ↗
 
Via Benzinga
News headline image
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More ↗
 
Via Benzinga
News headline image
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine CEO Issues Letter to Shareholders
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More ↗
 
Via Benzinga
News headline image
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence ↗
 
Via Benzinga
News headline image
Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More ↗
 
Via Benzinga
Topics Economy
News headline image
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket ↗
Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results. 
Via Benzinga
News headline image
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review ↗
 
Via Benzinga
News headline image
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Podcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive Behaviors ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.